URBANDALE, IA, July 24, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company research collaborator Professor Kevin Hodgetts has been awarded a grant of $300,000 by the nonprofit organization Cure SMA for the project Pre-Clinical Development of LDN-5178 for the Treatment of SMA.

“Cure SMA's support of Professor Hodgetts to work with Dr. Elliot Androphy and other collaborators on SMA drug candidate LDN-5178 represents an important validation of Spotlight Innovation's preclinical SMA pipeline,” said Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development.

Spotlight Innovation holds an exclusive, worldwide development and commercialization license from Indiana University Innovation and Commercialization Office for LDN-5178 and a group of related compounds including STL-182.

Professor Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital, and Dr. Androphy of Indiana University School of Medicine, are members of Spotlight Innovation's Scientific Advisory Board.

For more information about Cure SMA and this grant award, visit www.curesma.org/news/hodgetts-grant-2018.html.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). Spotlight Innovation’s development pipeline includes product candidates for cancer, chronic pain, spinal muscular atrophy (SMA) and Zika virus infection. At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com or www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation’s efforts to develop and commercialize various therapies, including LDN-5178 and STL-182, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the therapies; the inability to hire appropriate staff to develop the therapies; unforeseen technical difficulties in developing the therapies; the inability to obtain regulatory approval for human use; competitors’ therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation’s periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact:
Rene Erickson
Spotlight Innovation Inc.
1-515-274-9087
[email protected]

URBANDALE, IA, July 10, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that the Company has entered into a multi-year partnership agreement with Des Moines, IA-based Hip-Hope Inc., an organization dedicated to utilizing arts and culture to promote, advocate and support hope for at-risk youth wherever symptoms of hopelessness are prevalent.

Hip-Hope is helping to strengthen the community of greater Des Moines by providing programs and services that promote mental health wellness, healthy and active lifestyles, safety, and security. Hip-Hope's programs include, but are not limited to, arts and culture, music production, artistic expression, social development, conflict resolution, gang intervention, life skills, critical thinking, mentoring, community engagement, and career readiness.

“While our two organizations may appear different on the surface, the work of both Hip-Hope and Spotlight Innovation is laser focused on addressing unmet needs,” said John Krohn, Spotlight Innovation’s President and Chief Executive Officer. “Whether it’s providing programs to keep kids safe and poised for success, or developing treatments for rare diseases that affect children, together we have the potential to enrich and save lives.”

Bo James, Founder and Executive Director of Hip-Hope, said, "All of our kids are at risk and exhibit symptoms of hopelessness, underprivileged and affluent alike. Some are in the foster care system, have experienced trauma, bouts with depression and suicidal thoughts. Many have been engaged in violent activities, are struggling academically and have considered dropping out of school. In some cases, our kids have one or both parents incarcerated, and drug addiction is prevalent in their households.”

James continued, saying, “We have a mantra, 'Hope Says Nope to Dope', and that's one reason we're so excited to partner with Spotlight Innovation. Like us, they have a passion for improving the lives of children and recognize that drug addiction has wide-spread implications for families and communities. The growing concern of prescription drug misuse lead them to develop their non-addictive chronic pain relief product, Venodol.”

As part of the partnership, Spotlight Innovation is the title sponsor for Hip-Hope’s 2018 “#kidslivesmatter FUNraiser Challenge” to be held August 3, 2018, at the 7 Flags Event Center in Clive, IA. The annual event is a youth empowerment campaign designed to build kids’ character, physical health, and self-esteem.

About Hip-Hope Inc.

Hip-Hope Inc. is a non-profit organization, with 501(C)3 tax exempt status, whose mission is to utilize arts and culture to promote, advocate and support Hope wherever symptoms of hopelessness are prevalent. Hip-Hope defines hopelessness as: “Being unable to function or maintain a desired quality of life due to lack of knowledge, resources, mental health and/or access to solutions.” Hip-Hope’s primary focus is on addressing community safety concerns and disparities as they relate to economics, health, incarceration and education among “at-risk” and “high-risk” youth ages K-12 in the greater Des Moines area. For more information, visit http://www.hiphopeinc.org or www.kidslivesmatter.net.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). Spotlight Innovation’s development pipeline includes product candidates for cancer, chronic pain, spinal muscular atrophy (SMA) and Zika virus infection. At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com or www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation’s efforts to develop and commercialize its various therapies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the therapies; the inability to hire appropriate staff to develop the therapies; unforeseen technical difficulties in developing the therapies; the inability to obtain regulatory approval for human use; competitors’ proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation’s periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Press Contact
Rene Erickson
Spotlight Innovation Inc.
1-515-274-9087
[email protected]

URBANDALE, IA, June 12, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company research collaborator and Scientific Advisory Board member Professor Hengli Tang has co-authored an article, published in Cell Discovery on June 5, 2018, reporting potent antiviral activity and in-vivo efficacy of two small molecule drugs (emetine and cephaeline) against Zika virus (ZIKV) infection.

The article is available at https://www.nature.com/articles/s41421-018-0034-1.

“These small molecule compounds may prove to be viable drug candidates, and we are excited that Professor Tang and his collaborators continue to advance the field of anti-ZIKV therapies,” said Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development.

Funding provided by Spotlight Innovation under a Sponsored Research Agreement with Florida State University is enabling Tang and his collaborators to expand on their discoveries and to accelerate the development of safe and effective drugs to treat patients infected with ZIKV. Spotlight Innovation has obtained from the Florida State University Research Foundation exclusive, worldwide rights to develop and commercialize certain compounds for the treatment of viral infections, including Zika virus infection.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com or www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation’s efforts to develop and commercialize its various therapies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the therapies; the inability to hire appropriate staff to develop the therapies; unforeseen technical difficulties in developing the therapies; the inability to obtain regulatory approval for human use; competitors’ proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation’s periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Press Contact:
Spotlight Innovation Inc.
Rene Erickson
1-515-274-9087
[email protected]

URBANDALE, IA, April 18, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Celtic Biotech Iowa, Inc., reported results from Cohort 1 and Cohort 2 of its Phase I Crotoxin clinical trial at the American Association for Cancer Research (AACR) 2018 Annual Meeting.

Results from Phase I Cohort 1, Innovative design for a phase I trial with intra-patient dose escalation: The Crotoxin study, indicated that intra-patient dose escalation can be achieved without any observed serious drug-related adverse effects. Additionally, patient pain impact questionnaires conducted concurrent with treatment suggested that Crotoxin provided analgesic activity.

Results from Phase I Cohort 2, Continuous i.v. Crotoxin in advanced cancer: Intra-patient dose escalation, indicated that faster dose escalation was achievable. Evaluation of antitumor response showed that two of the six subjects had stable disease on Day 36.

The protocol for Phase I Cohort 2 was developed with the guidance the Company’s Contract Research Organization (CRO), ImmunoClin Ltd. The protocol included the innovative use of a portable infusion pump to permit continuous round-the-clock drug administration with remote monitoring, facilitating at-home treatment for patients.

A revised protocol, Phase 1 Cohort 3, incorporating faster and higher dosing regimes than Cohort 2, has been approved by the French National Agency for Medicines and Health Products Safety (ANSM). ImmunoClin Ltd will continue as the Company’s CRO for the Cohort 3 investigation.

Abstracts for the studies are available online:
Phase 1 Cohort 1: http://www.abstractsonline.com/pp8/#!/4562/presentation/11207
Phase 1 Cohort 2: http://www.abstractsonline.com/pp8/#!/4562/presentation/11208

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit spotlightinnovation.com or twitter.com/spotlightinno.

About Celtic Biotech Iowa, Inc.

Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., is developing novel therapeutic products for the treatment of cancer. Derived from specialized receptor binding proteins found in snake venom, these product candidates have the potential to reduce treatment costs, increase survival, and improve quality-of-life for cancer patients.

About the ImmunoClin Limited

ImmunoClin Limited is a UK healthcare company that has been providing quality research and development services to industry for over 17 years.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include, but are not limited to, statements regarding efforts by Spotlight Innovation and Celtic Biotech Iowa to develop and commercialize various therapies, to achieve stated benchmarks, and the anticipated revised protocol, Phase 1 Cohort 3. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: uncertainties inherent in clinical trials; the inability to finance the planned development of the therapies; the inability to hire appropriate staff to develop the therapies; unforeseen technical difficulties in developing the therapies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Press Contact
Rene Erickson
Spotlight Innovation Inc.
1-515-274-9087
[email protected]

URBANDALE, IA, March 28, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Celtic Biotech Iowa, Inc., will present two posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 14-18, 2018, at the McCormick Place Convention Center in Chicago, IL.

“We look forward to sharing at the AACR Annual Meeting details of the progress we've made advancing Crotoxin through early clinical trials," said Dr. Paul Reid, President of Celtic Biotech Iowa.

Poster presentations:

Title: Innovative design for a phase I trial with intra-patient dose escalation: The Crotoxin study
Date and Time: Monday April 16, 2018 from 8:00 AM - 12:00 PM CDT
Location: Poster Section 42, Exhibit Hall A, McCormick Place South
Abstract Number: CT070, Poster Board Number 23
Presenting Author: Dr. Jacques Medioni, Centre for Early-Phase Trials in Cancer (CEPEC), Hôpital Européen Georges Pompidou, Paris, France, and Paris Descartes University, Paris, France

Title: Continuous i.v. Crotoxin in advanced cancer: Intra-patient dose escalation
Date and Time: Monday April 16, 2018 from 8:00 AM - 12:00 PM CDT
Location: Poster Section 42, Exhibit Hall A, McCormick Place South
Abstract Number: CT071, Poster Board Number 24
Presenting Author: Dr. Marian Gil-Delgado, Medical Oncology Service University Hospital Pitié-Salpêtrière, Paris, France

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit spotlightinnovation.com or twitter.com/spotlightinno.

About Celtic Biotech Iowa, Inc.

Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., is developing novel therapeutic products for the treatment of cancer. Derived from specialized receptor binding proteins found in snake venom, these product candidates have the potential to reduce treatment costs, increase survival, and improve quality-of-life for cancer patients.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include, but are not limited to, statements regarding efforts by Spotlight Innovation and Celtic Biotech Iowa to develop and commercialize various therapies, and to achieve stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: uncertainties inherent in clinical trials; the inability to finance the planned development of the therapies; the inability to hire appropriate staff to develop the therapies; unforeseen technical difficulties in developing the therapies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact:
Rene Erickson
Spotlight Innovation Inc.
1-515-274-9087
[email protected]

URBANDALE, IA, March 13, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that U.S. Patent No. 9,895,358 entitled Combination Therapies for Treatment of Spinal Muscular Atrophy has been issued to Indiana University Research and Technology Corp. and The Brigham and Women’s Hospital, Inc. The patent discloses compositions and methods for the treatment of spinal muscular atrophy (SMA), including STL-182 and related compounds, to which Spotlight Innovation holds an exclusive, worldwide commercial license.

The patent’s inventors include Dr. Elliot Androphy of the IU School of Medicine and Prof. Kevin Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital. A research collaboration between the inventors led to synthesis and early preclinical testing of STL-182. Dr. Androphy and Prof. Hodgetts are members of Spotlight Innovation's Scientific Advisory Board.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com or www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation’s efforts to develop and commercialize various product candidates, including STL-182, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of STL-182; the inability to hire appropriate staff to develop STL-182; unforeseen technical difficulties in developing STL-182; the inability to obtain regulatory approval for human use; competitors’ therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation’s periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact:
Rene Erickson
Spotlight Innovation Inc.
1-515-274-9087
[email protected]

Venodol® is a Non-opioid, Non-addictive, Over-the-Counter Alternative to Opioids and NSAIDs for the Treatment of Chronic Pain

URBANDALE, IA, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Caretta Therapeutics’ new over-the-counter chronic pain relief product, Venodol Roll-on, is now available for purchase at Amazon.com.

“We are pleased to offer Venodol Roll-on to Amazon’s loyal customers,” said John Krohn, Spotlight Innovation’s President and Chief Executive Officer. “We believe that Venodol can provide significant relief for chronic pain, without the fear of forming an addiction. The product’s availability at Amazon.com will increase awareness and provide access for the many consumers who may benefit from Venodol’s pain-relieving qualities.”

Visit Amazon.com to purchase Venodol Roll-on:
https://www.amazon.com/dp/B07896N2GM

About Venodol

Venodol is a homeopathic, non-opioid, non-addictive, non-steroidal analgesic that does not contain other non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, naproxen sodium or ibuprofen, and it does not contain acetaminophen. Venodol’s active ingredient, cobra venom, is listed as an analgesic in the Homeopathic Pharmacopoeia of the United States (HPUS). The topical roll-on format of Venodol is the first to be introduced to the market. Venodol Roll-on is formulated to provide long-lasting relief from chronic pain associated with inflammation, including joint pain, tendinitis, arthritis (excluding osteoarthritis), and body aches. In the coming months Caretta Therapeutics plans to introduce additional Venodol product formats. Venodol Roll-on is also available for purchase online at venodol.com.

About Caretta Therapeutics, LLC

Caretta Therapeutics, LLC, develops and markets over-the-counter (OTC) analgesic products formulated to provide relief from chronic pain associated with inflammation. Caretta Therapeutics is a subsidiary of Spotlight Innovation Inc.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com or www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation’s efforts to develop and commercialize Venodol and related products, to achieve its stated benchmarks, and the effects of Venodol. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of Venodol and related products; the inability to hire appropriate staff to develop Venodol and related products; unforeseen technical difficulties in developing Venodol and related products; competitors’ therapies proving to be more effective, cheaper or otherwise more preferable; the inability to market a product; or, failure by customers to achieve the desired effects of Venodol and related products. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation’s periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Press Contact
Rene Erickson
Spotlight Innovation Inc.
(515) 274-9087
[email protected]
Investor Contact
Stephanie Prince
PCG Advisory Group
(646) 762-4518
[email protected]

The corporate partner relationship encompasses Hawkeye Football, Men's Basketball and Wrestling during the respective athletic seasons, and focuses on network radio and social media visibility. During the Hawkeye Football season, Venodol Roll-on advertisements will air on the Hawkeye Radio Network during game broadcasts, and Venodol will serve as the Presenting Sponsor of the Venodol Keys to the Game. Venodol will also receive significant brand exposure during the weekly Hawk Talk with Kirk Ferentz program. During Hawkeye Men's Basketball season, advertisements will air during game broadcasts and Venodol will serve as the Presenting Sponsor of the Venodol Keys to the Game, and Venodol will have a bolstered presence on the weekly call-in show Hawk Talk with Fran McCaffery. Venodol will also be an active sponsor with Hawkeye Wrestling Radio, and will be a partner throughout a large portion of the athletics season on UI Athletics' Official Twitter and Facebook accounts, serving as the Presenting Sponsor for numerous tweets and posts originated by UI Athletics.

"We're pleased to be working with Spotlight Innovation, helping to broaden reach for Venodol through many Hawkeye avenues such as the radio network, and UI Athletics' official social media accounts. We appreciate their commitment to Iowa and welcome them to the corporate partner family," said Hawkeye Sports Properties Vice President and General Manager Gabe Aguirre.

"We are delighted to partner with University of Iowa Athletics and Hawkeye Sports Properties to increase brand recognition for Venodol," said John Krohn, Spotlight Innovation's President and Chief Executive Officer. "Both Spotlight Innovation and Caretta Therapeutics are based in Iowa so we're excited to introduce Venodol to our fellow Hawkeye fans."

About Venodol Roll-on
Venodol Roll-on is formulated to provide long-lasting relief from chronic pain associated with inflammation, including joint pain, tendinitis, arthritis (excluding osteoarthritis), and body aches. The product is a homeopathic, non-opioid, non-addictive, non-steroidal topical analgesic that is easy-to-use and scent-free. Venodol does not contain other non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, naproxen sodium or ibuprofen, and it does not contain acetaminophen. Venodol's active ingredient, cobra venom, is listed as an analgesic in the Homeopathic Pharmacopoeia of the United States (HPUS). Venodol is available for purchase on-line at venodol.com.

About Learfield
An industry leader for more than four decades, Learfield has a deep presence in the college athletics landscape nationwide. In addition to Iowa, it manages the multimedia and sponsorship rights for nearly 130 collegiate institutions, conferences and arenas, and supports athletic departments at all competitive levels as title sponsor of the prestigious Learfield Directors' Cup. Learfield also provides its collegiate partners access to professional concessions and ticket sales; branding, licensing and trademark consulting; digital and social platform expertise; campuswide business and sponsorship development; and venue and technology systems through its affiliated companies.

About Caretta Therapeutics, LLC
Caretta Therapeutics, LLC, develops and markets over-the-counter (OTC) analgesic products formulated to provide relief from chronic pain associated with inflammation. In the coming months, Caretta Therapeutics plans to introduce additional Venodol product formats and to expand distribution to mass merchandise retailers through its Master Broker Agreement with a premier global distribution brokerage firm. Caretta Therapeutics, based in Urbandale, IA, is a subsidiary of Spotlight Innovation Inc.

About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com or www.twitter.com/spotlightinno.

Forward-Looking Statements
Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various therapies, to achieve its stated benchmarks, the effects of Venodol, and plans to introduce additional Venodol product formats and to expand distribution. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the therapies; the inability to hire appropriate staff to develop the therapies; unforeseen technical difficulties in developing the therapies; the inability to obtain regulatory approval for human use; competitors' proving to be more effective, cheaper or otherwise more preferable; or, failure by customers to achieve desired effects of Venodol. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Media Contact
Rene Erickson
Spotlight Innovation Inc.
1-515-274-9087
[email protected]

Investor Contact
PCG Advisory Group
Stephanie Prince
1-646-762-4518
[email protected]

Source: Spotlight Innovation Inc.

URBANDALE, Iowa, Aug. 16, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company has entered into a Sponsored Research Agreement with Indiana University to support research directed by Elliot Androphy, M.D., aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy (SMA). Dr. Androphy is a member of Spotlight Innovation's Scientific Advisory Board and a co-inventor of STL-182, the Company's lead product candidate for SMA.

Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Dr. Androphy is a prolific researcher and highly-respected thought leader. We are privileged to work with him to develop novel therapies for SMA."

Dr. Androphy is the Chair of the Department of Dermatology of Indiana University School of Medicine and has published widely in high-impact journals including Science, Nature, EMBO Molecular Medicine, Human Molecular Genetics, Journal of Virology, and Molecular Cell. He served as Vice Chair for Research of the Department of Medicine and Director of the M.D./Ph.D. Program at the University of Massachusetts Medical School where his lab characterized the disease-causing mechanism of alternative splicing of the SMN2 gene. At Indiana University School of Medicine, Dr. Androphy has used a novel, cell-based high throughput screen for compounds that increase levels of the SMN protein. This work has led to the identification of pre-clinical drug candidates for SMA.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize various product candidates, including STL-182, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of STL-182; the inability to hire appropriate staff to develop STL-182; unforeseen technical difficulties in developing STL-182; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

View original content with multimedia:http://www.prnewswire.com/news-releases/spotlight-innovation-enters-into-sponsored-research-agreement-with-indiana-university-to-develop-new-therapies-for-spinal-muscular-atrophy-300505024.html

SOURCE Spotlight Innovation Inc.

URBANDALE, Iowa, June 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company has entered into a Sponsored Research Agreement with Brigham and Women's Hospital (BWH) to support research directed by Kevin Hodgetts, Ph.D., aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy (SMA).

Professor Hodgetts is a member of Spotlight Innovation's Scientific Advisory Board and a co-inventor of STL-182, the Company's lead product candidate for SMA. He is the head of Medicinal Chemistry and Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN) at Brigham and Women's Hospital, and Assistant Professor of Neurology at Harvard Medical School. Prof. Hodgetts is also the Founder and co-Chair of the Scientific Advisory Board of Klogene Therapeutics, Inc., and has a broad background in organic and medicinal chemistry with experience in both industrial and academic drug discovery. He has over 15 years of experience working on treatments for diseases of the central nervous system. Prof. Hodgetts joined the LDDN in September 2012 to work with the academic community to design new and innovative strategies for drug discovery for neurodegenerative diseases.

Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Professor Hodgetts is an accomplished medicinal chemist and a pioneer in the synthesis of novel compounds with the potential to treat SMA. We are thrilled that he has chosen to collaborate with us to develop treatments for this devastating illness."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize various product candidates, including STL-182, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of STL-182; the inability to hire appropriate staff to develop STL-182; unforeseen technical difficulties in developing STL-182; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-enters-into-sponsored-research-agreement-to-develop-new-therapies-for-spinal-muscular-atrophy-300482508.html

SOURCE Spotlight Innovation Inc.

URBANDALE, Iowa, June 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that the Company has engaged PCG Advisory Group (PCG) to provide investor relations services in support of the Company and its drug development programs, and to strengthen its connection to the investment community.

"We are pleased to partner with PCG, a pioneering integrated communications firm, to energize our investor relations activities," said John Krohn, Spotlight Innovation's President and Chief Executive Officer. "We believe PCG is well-suited to explain our ongoing efforts to develop novel therapeutic product candidates for rare diseases. Moreover, as we bring to market Venodol, our first over-the-counter analgesic, we consider PCG to be the ideal firm to educate investors about this breakthrough product."

"Spotlight Innovation has a unique business model and investment story to tell that we believe will resonate on Wall Street and beyond. We look forward to working together to communicate their value proposition to our broad network of investors, bloggers, journalists, and other key stakeholders," said Jeff Ramson, Founder and CEO of PCG.

About PCG Advisory Group

Founded in 2008 and headquartered in New York City, PCG Advisory Group is dedicated to the delivery of top tier investor relations, strategic advisory, communications, and innovative digital media services for the micro and small cap public company marketplace. PCG has extensive experience with life sciences, technology, energy and other emerging growth companies, both in the US and internationally.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-engages-investor-relations-firm-pcg-advisory-group-300482466.html

SOURCE Spotlight Innovation Inc.

URBANDALE, Iowa, June 22, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company will participate in a family-friendly research poster session at the Cure SMA 2017 Annual SMA Conference, which the Company is supporting as a Silver Sponsor. On Friday, June 30, 2017, in the Fantasia Ballroom at Disney's Contemporary Resort in Orlando, FL, Dr. Geoffrey Laff will present a poster entitled STL-182, an Orally-available Small Molecule that Stabilizes SMN Protein.

"We are proud to be a sponsor of this year's Cure SMA Annual SMA Conference and to present a poster designed to help families directly affected by SMA gain a better understanding of the disease," said Dr. Laff, Spotlight Innovation's Senior Vice President of Business Development.

The 2017 Annual SMA Conference will be held from June 29 to July 2 at Walt Disney World in Orlando. Nearly 2,000 attendees, including researchers, families, and medical care providers, are expected to participate.

Spotlight Innovation is developing STL-182, an orally-available small molecule that may have therapeutic potential for treating spinal muscular atrophy (SMA). SMA is an autosomal recessive disorder that is a leading genetic cause of death in infants and toddlers. Synthesis and early preclinical testing of STL-182 were accomplished through a research collaboration between Professors Elliot Androphy of Indiana University School of Medicine and Kevin Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital. Their work was supported in part by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Child Health and Human Development (NICHD).

Spinal muscular atrophy affects between 1 in 6,000 and 1 in 10,000 newborns. Approximately 1 in 40 to 1 in 50 adults have only a single intact spinal motor neuron 1 (SMN1) gene, which encodes a protein (SMN) required for proper neuromuscular function. An infant who inherits no intact SMN1 gene from either parent may develop SMA and lose the ability to sit, stand, walk, swallow, and/or breathe. In about 60% of cases, patients with SMA die by age two.

Even in SMA patients, low levels of functional SMN protein are produced by an SMN1-related gene called SMN2. One therapeutic strategy to treat SMA is to increase levels of functional SMN protein encoded by SMN2. In mouse models of SMA, STL-182 may restore neuromuscular function by stabilizing endogenous SMN protein.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize various product candidates, including STL-182, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of STL-182; the inability to hire appropriate staff to develop STL-182; unforeseen technical difficulties in developing STL-182; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-to-present-poster-at-the-cure-sma-2017-annual-sma-conference-300478340.html

SOURCE Spotlight Innovation Inc.

URBANDALE, Iowa, June 21, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that on June 15, 2017, it was made aware by OTC Markets of promotional activities surrounding the Company's common stock.

According to the OTC Markets the activities were promotional newsletter emails encouraging investors to purchase the Company's common stock and this promotional activity coincided with higher than average trading volume and fluctuations in the Company's stock price. The Company was unaware of the promotional activity until informed by OTC Markets, and is unaware of the full nature of the promotional activity, the extent of the email dissemination, or the responsible parties.

In its investigation into this matter, the Company has made direct inquiries of its executive officers, directors, its controlling shareholders (i.e., shareholders owning 10% or more of the Company's securities) and its third party service providers. Neither the Company, nor its executive officers, directors or, to the Company's knowledge, its controlling shareholders (i.e., shareholders owning 10% or more of the Company's securities) have been involved in any way with the creation or distribution of promotional materials including these email newsletters. Additionally, neither the Company's executive officers, directors nor, to the knowledge of the Company, any controlling shareholders or any third party service providers, sold or purchased shares of Common Stock of the Company within the last 90 days, except as it relates to the purchase of convertible instruments as described in our periodic reports with the Securities and Exchange Commission. Further, the Company has not, other than disclosed in its periodic reports filed with the Securities and Exchange Commission, issued any shares or convertible instruments allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance. From January 2016 to June 2016 the Company engaged CEOCast, and since July 25, 2016 the Company has engaged IRTH Communications as its provider of investor relations services, public relations services, marketing, or other related services. The Company has made direct inquiries of its current investor relations service provider concerning whether they have directly or indirectly been involved in any way, including payment of a third party, with the creation or distribution of promotional materials related to the company and its securities. This vendor has declined to comment on said promotional activities.

The Company is not affiliated in any way with the authors of these promotional newsletter emails. Certain statements contained in the promotional materials as supplied to the Company by OTC Markets may be materially false and/or misleading. The Company encourages those interested in the Company to rely solely on information included in its press releases combined with its filings and disclosures made with the Securities and Exchange Commission.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-inc-issues-statement-about-recent-stock-trading-activity-300477991.html

SOURCE Spotlight Innovation Inc.

URBANDALE, Iowa, June 14, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that its subsidiary Caretta Therapeutics, LLC, has signed a manufacturing agreement with Orlando, FL-based contract manufacturing organization (CMO) Maitland Labs, LLC, for the production of the active pharmaceutical ingredient (API) for Venodol, the Company's first over-the-counter product for the treatment of chronic pain. Maitland Labs is the second CMO producing Venodol's API on behalf of Caretta Therapeutics. The primary CMO has completed the initial API production run, and commercial production of Venodol is expected to begin soon.

"We continue to develop partnerships with premier CMOs and supply chain vendors for every step in the Venodol production process, and we are pleased to have Maitland Labs as a member of our team," said John Krohn, Spotlight Innovation's President and Chief Executive Officer.

Venodol topical roll-on is formulated to relieve chronic pain associated with inflammation, including joint pain, tendinitis, and arthritis (excluding osteoarthritis). Venodol is tentatively scheduled to be available in the United States in summer 2017. Caretta Therapeutics plans to introduce additional product formats formulated to provide non-addictive alternatives to opioid drugs for the relief of chronic pain.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize Venodol and additional product formats, and to achieve its stated benchmarks, including but not limited to the production, development and sales of Venodol. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop Venodol; unforeseen technical difficulties in developing and producing Venodol; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; the inability to market a product; or the inability to achieve sales of Venodol. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-subsidiary-caretta-therapeutics-signs-second-venodol-api-production-agreement-300473628.html

SOURCE Spotlight Innovation Inc.

URBANDALE, Iowa, June 8, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that former Chief Executive Officer Cristopher Grunewald has agreed to return 1,618,627 shares of common stock to the Company treasury. The shares being returned are in addition to the prior return by Mr. Grunewald of 1,000,000 shares of common stock to the Company treasury in the first quarter of 2017. Concurrent with the May 2017 stock surrender agreement, Mr. Grunewald entered into a consulting agreement which provided for Mr. Grunewald to be engaged as a consultant to the Company for two years and to receive a warrant to purchase up to 500,000 shares of common stock at an exercise price of $1.25 per share for a term of three years.

"Mr. Grunewald continues to show his strong support for the Company. His share returns reduce the number of outstanding shares of the Company which increases the percentage of ownership for all shareholders, and his acceptance of the warrant with an exercise price above the current market price is a clear illustration of his belief in the positive long-term prospects of the Company," said John Krohn, Spotlight Innovation's President and Chief Executive Officer.

Said Mr. Grunewald, "I believe these share returns are in the best interests of the Company and its shareholders, and I have every confidence in the Company's corporate leadership and life science professionals."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-former-ceo-returning-additional-16-million-shares-to-company-treasury-300470846.html

SOURCE Spotlight Innovation Inc.

URBANDALE, Iowa, May 31, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that subsidiary Caretta Therapeutics, LLC, has begun the process of manufacturing Venodol topical roll-on, a non-addictive alternative to opioid and steroidal analgesics intended to provide relief from chronic pain. The manufacturing of Venodol is taking place at contract manufacturing organization (CMO) facilities located in Florida in the United States.

Commenting on the start of the manufacturing process, John Krohn, Spotlight Innovation's President and Chief Executive Officer, said, "Commencing production is an exciting milestone in our efforts to bring Venodol to the commercial market. We believe there is significant demand for non-addictive remedies that have the potential to improve quality-of-life for the millions of people who suffer from chronic pain, and we are looking forward to offering Venodol to consumers in the near future."

Venodol topical roll-on is formulated to relieve chronic pain associated with inflammation, including joint pain, tendinitis, and arthritis (excluding osteoarthritis). Venodol is tentatively scheduled to be available in the United States in summer 2017. Caretta Therapeutics plans to introduce additional product formats formulated to provide non-addictive alternatives to opioid drugs for the relief of chronic pain.

According to the American Society of Addiction Medicine's Opioid Addiction 2016 Facts & Figures, in 2015, two million Americans 12 or older had a substance use disorder involving prescription pain relievers, and there were more than 20,000 accidental overdose deaths related to prescription pain relievers.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies and products, including but not limited to Venodol, and to achieve its stated benchmarks including, without limitation, statements relating to if and when Caretta Therapeutics will succeed in making available products it is developing. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include: risks and uncertainties, such as the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-subsidiary-caretta-therapeutics-begins-the-manufacturing-process-for-venodol-a-new-over-the-counter-product-to-treat-chronic-pain-300465850.html

SOURCE Spotlight Innovation Inc.

URBANDALE, Iowa, May 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that June Beetler, D.O., has been appointed to the Company's Board of Directors. Dr. Beetler joins current board members John M. Krohn, Craig A. Lang, Dr. Sanjeev Agarwal, and Ralph Arthur.

"Dr. Beetler has expansive medical knowledge and hands-on patient care experience, and we are delighted to have such an outstanding practitioner join us," said John Krohn, Spotlight Innovation's President and Chief Executive Officer. "She brings to our boardroom valuable perspective and proven leadership skills, and we look forward to benefiting from her insight and guidance."

"I welcome the opportunity to work with the outstanding business and life science professionals at Spotlight Innovation," said Dr. Beetler. "I'm excited to join the team during this period of growth and to assist in developing the Company's pipeline product candidates."

Dr. Beetler is Board Certified in Pediatrics and has over 20 years of experience in general practice and urgent care settings. Her experience and expertise span general pediatrics, integrative medicine and holistic care. She currently holds a medical license in Florida and practices at St. Petersburg Pediatrics in St. Petersburg, Florida. Before relocating to Florida, Dr. Beetler maintained her own practice, Johnston Pediatric Clinic, P.C., for 18 years, and was a staff physician at Iowa Lutheran Hospital, Iowa Methodist Medical Center, and Mercy Medical Center - Des Moines. As a former biology and chemistry instructor, Dr. Beetler imparted her knowledge to college, high school and secondary school students, and she has mentored medical students on overcoming the day-to-day obstacles encountered in the clinical setting. She earned her Doctor of Osteopathic Medicine at Des Moines University, and completed her residency at Blank Children's Hospital at Iowa Methodist Medical Center.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-appoints-dr-june-beetler-to-board-of-directors-300465188.html

SOURCE Spotlight Innovation Inc.

URBANDALE, Iowa, May 23, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company's Board of Directors has accepted the resignation of Cristopher Grunewald as Chief Executive Officer (CEO) and appointed John M. Krohn as interim CEO, effective immediately. Mr. Krohn will continue to serve as Chairman of the Board, President and Chief Operating Officer. In connection with the transition, the Company has entered into a consulting agreement with Mr. Grunewald. The Board of Directors will take the appropriate amount of time to evaluate and select a permanent CEO with experience in both management and healthcare.

Mr. Krohn joined the Company's Board of Directors in February 2016. He has over three decades of operating and leadership experience across diverse industry sectors. His expertise includes corporate financial management, strategic financial advisory, private and public equity and debt financing, and M&A strategy and execution.

"Spotlight Innovation has assembled outstanding internal scientific talent, led by Dr. Geoffrey Laff, along with a superb Scientific Advisory Board. Guidance from these life sciences experts will allow me to lead the Company effectively without a long personal history in the healthcare space," Mr. Krohn stated. "However, the Board of Directors recognizes that a CEO with a track record in drug development and healthcare may be best positioned to help realize our team's passion and commitment to building a successful pharmaceutical company. I would like to thank Cris for his contributions as founder and CEO."

Mr. Krohn continued, "While we are selecting the right permanent CEO, we will remain focused on the Company's strategic priorities: supporting our product development programs, identifying additional business opportunities, implementing cost-efficiency measures, and creating value for shareholders."

"I am very proud of our team and what we've accomplished to date," said Mr. Grunewald. "In addition, I am deeply committed to providing all possible assistance to the Company and am extremely confident in the leadership moving forward."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-appoints-john-krohn-interim-chief-executive-officer-300461914.html

SOURCE Spotlight Innovation Inc.